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Abstract
Cells are continuously exposed to diverse stimuli ranging from soluble endocrine and paracrine
factors to signalling molecules on neighbouring cells. Receptors of the tyrosine kinase family play
an important role in the integration and interpretation of these external stimuli, allowing a cell to
respond appropriately to its environment. The activation of receptor tyrosine kinases (RTKs) is
tightly controlled, allowing a normal cell to correctly integrate its external environment with internal
signal transduction pathways. In contrast, due to numerous molecular alterations arising during
the course of malignancy, a tumour is characterized by an abnormal response to its environment,
which allows cancer cells to evade the normal mechanisms controlling cellular proliferation.
Alterations in the expression of various RTKs, in their activation, and in the signalling molecules
lying downstream of the receptors play important roles in the development of cancer. This topic is
the major focus of the thematic review section of this issue of Breast Cancer Research.
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EGF = epidermal growth factor; ER = oestrogen receptor; FGF = fibroblast growth factor; GPCR = G-protein-coupled receptor; IGF = insulin-like
growth factor; MMTV = mouse mammary tumour virus; PLC = phospholipase C; RTK = receptor tyrosine kinase.
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Receptors of the tyrosine kinase family play an important
role in the integration and interpretation of diverse extra-
cellular stimuli, allowing a cell to respond appropriately to
its environment. All members of this superfamily have in
common an extracellular ligand-binding domain, a single
membrane-spanning region and a cytoplasmic protein
tyrosine kinase domain. Ligand binding promotes receptor
dimerization, consequently stimulating kinase activity and
triggering autophosphorylation of specific tyrosine residues
within the cytoplasmic domain (for review [1]). These
phosphorylated residues serve as docking sites for pro-
teins that are involved in regulation of intracellular sig-
nalling cascades. The activation of RTKs is generally
tightly controlled, allowing a normal cell to integrate exter-
nal stimuli with internal signal transduction pathways cor-
rectly. In contrast, due to numerous molecular alterations
that arise during the course of malignancy, a tumour is
characterized by an abnormal response to its environment,
which allows cancer cells to evade the normal mecha-
nisms that control cellular proliferation.
Alterations in RTK expression and activation, and in the
signalling molecules that lie downstream of the receptors
play important roles in the development of cancer. This
topic is the major focus of the thematic review section of
the present issue of Breast Cancer Research. In particu-http://breast-cancer-research.com/content/2/3/154
lar, Stern [2] writes on the interactions among the ErbB
family members [epidermal growth factor (EGF) receptor,
ErbB2, ErbB3 and ErbB4]; Andrechek and Muller [3]
present information gleaned from transgenic models of
mammary cancer developed with Neu, the rat ErbB2
equivalent; and Prenzel et al [4] describe the emerging
role of the EGF receptor as an integrator for other classes
of membrane receptors. The non-RTK Src is hyperactive in
breast cancer and, as discussed in the review by Biscardi
et al [5], there is a cooperative interaction between Src
and the EGF receptor, which very likely contributes to
malignancy. The insulin-like growth factor (IGF)-I signalling
cascade and its interaction with the oestrogen receptor
(ER) in breast tumours is discussed by Zhang and Yee
[6], and the role of fibroblast growth factors (FGFs) and
the cooperating Wnt signalling pathway in mammary
mouse tumour virus (MMTV)-induced mouse mammary
cancer is discussed by Dickson et al [7]. Finally, the signal
transducers that lie downstream of the tyrosine kinases
that have been implicated in breast cancer are reviewed
by Kairouz and Daly [8].
It has been known for almost 15 years that deregulated
expression of the EGF receptor and ErbB2 contribute to
the development and malignancy of breast cancer. In fact,
one of the first consistent genetic alterations found in
breast tumours was c-erbB2 gene amplification [9]. The
ErbB family has evolved from a single ligand–receptor
combination in C elegans, through Drosophila, which have
one receptor and four ligands, to vertebrates, in which four
ErbB receptors bind multiple EGF-related ligands. Conse-
quently, in vertebrates numerous ErbB homodimer and
heterodimer combinations are possible, reflecting the
greater complexity of receptors and ligands, and suggest-
ing that they have evolved to provide the high degree of
signalling diversity that is necessary for their development.
This complex ErbB receptor–ligand network and its role in
breast cancer is described in the article by Stern [2].
Src is overexpressed or highly activated in numerous types
of human cancers, including breast cancer. Src physically
interacts with both EGF receptor and ErbB2, and has been
implicated in the transformation process induced by both
RTKs. Evidence arising from various types of experiments
indicates the significance of Src in normal EGF receptor
signalling. Src plays an important role in EGF receptor acti-
vation, because it phosphorylates the receptor at Tyr 845
in the activation loop, stimulating its kinase activity [10].
Furthermore, Src and EGF receptor reciprocally interact
and appear to cooperate in the process of malignancy [5].
The mechanism that underlies the Src–ErbB2 interaction is
less clear than that described for Src–EGF receptor.
However, mammary tumours from Neu transgenic mice
display elevated Src kinase activity compared with the
adjacent normal epithelium [11], suggesting that there is
cooperativity in transformation.
As discussed in the article by Prenzel et al [4], RTKs do
not act in isolation but are integral components in the
complex signalling network that is necessary for the
correct response of a cell to its environment. There is a
wealth of data that show that EGF receptor in particular
becomes activated, serving as a convergence point for
other classes of membrane receptors, including G-protein
coupled receptors (GPCRs), cytokine receptors and inte-
grins. GPCR-induced EGF receptor activation has been
considered to be ligand-independent because of the
rapidity of the response, among other reasons. Intriguingly,
it has recently been shown [12] that GPCR-mediated
EGF receptor activation involves the stimulation of a met-
alloproteinase activity, which cleaves membrane-bound
pro-HB-EGF, one of the ligands for EGF receptor,
enabling it to bind and activate the kinase. Considering
the abundance of EGF receptor ligands expressed in
breast tumours, it is possible that autocrine EGF receptor
activation may in some instances arise from GPCR-medi-
ated ligand processing.
The signalling intermediates that act downstream of the
tyrosine kinases involved in breast cancer have also come
under scrutiny, as discussed in the article by Kairouz and
Daly [8]. Most of these proteins, including phospholipase
C (PLC)g, Shc, Grb2 and Grb7, have SH2 or phosphoty-
rosine binding domains, allowing them to bind to specific
phosphotyrosine residues in the activated RTKs. Many of
these signalling intermediates lie downstream of the ErbB
family and, not unexpectedly, some (eg PLCg) show
increased activity in tumours that overexpress ErbB RTKs.
Interestingly, EMS1, the human homologue of the Src sub-
strate cortactin, is amplified and overexpressed in approxi-
mately 15% of breast tumours [13]. Overexpression of
cortactin increases cell motility, and this is dependent on
Src-mediated tyrosine phosphorylation. These results
imply that during the process of malignancy there is not
only cooperativity between Src and ErbB RTKs, but also
selection for overexpression of a Src substrate that very
likely has a role in tumour progression, probably by
increasing the invasive or metastatic potential of breast
tumour cells.
IGF-I and its receptor have recently generated much inter-
est because of the ability of the receptor to inhibit apopto-
sis and the central role that it plays in oncogenic
transformation [14]. In fact it has been speculated that
IGF-I receptor activation is necessary to repress apoptosis
that would be induced by the uncontrolled activity of
certain oncoproteins. The fact that many oncoproteins,
including v-Src and EGF receptor, require functional IGF-I
receptor to transform cells gives support to this hypothe-
sis (for review [15]). The IGF-I receptor is expressed in vir-
tually all breast tumours. In addition to its role in
antiapoptic signalling moiety, there is a reciprocal interac-
tion between the IGF-I system and ER, which is describedBreast Cancer Research    Vol 2 No 3 Hynes
in the article by Zhang and Yee [6]. This interaction leads
to enhancement of the biological effects of oestrogens
and IGFs. Specifically, oestrogens induce the expression
of many of the players in the IGF-I network, including the
IGF-I receptor and the downstream signalling protein
insulin receptor substrate-1 [16], leading to an enhanced
cellular response to IGF-I. In primary human breast
cancers, insulin receptor substrate-1 levels correlate posi-
tively with ER levels. The negative effects of the antiestro-
gen tamoxifen on ER-positive tumour cells may in part be
due to downregulation of these important IGF-I signalling
molecules. Furthermore, high levels of IGF-I receptor sig-
nalling may impact on therapy, because the antiapoptotic
effects of this pathway might protect tumour cells from
radiation-induced death.
As discussed in the article by Dickson et al [7], there is
conflicting data on the importance of the FGF receptor
family in human breast cancer development. However,
inappropriate expression of FGF receptor ligands has a
clear role in murine mammary cancer. MMTV-induced
murine models of cancer have been extremely useful, not
only in discovering oncogenes that promote mammary
cancer, but also for identifying oncogenes that cooperate
in the induction of the tumours. MMTV induces cancer by
insertional mutagenesis, leading to activation/mutation of
genes at the genomic proviral insertion site. The first
proto-oncogene identified by MMTV proviral insertion was
Int-1/Wnt-1 [17]. An FGF family member, FGF-3, was
found at another site of MMTV insertion, and it was soon
recognized that many tumours contain proviruses at both
Wnt-1 and FGF-3. These results suggest that the combi-
nation of inappropriate FGF receptor signalling and activa-
tion of Wnt-1 and its downstream transcription factor Tcf
potently induces mammary cancer. In the future it will be
important to determine the role of FGF receptor signalling
in human breast cancer and to determine whether there is
a collaboration between Wnt-1 signalling and any of the
RTKs implicated in development of this malignancy.
A theme emerging from these articles is the concept of
cooperativity during the transformation process. I would
like to develop this idea using the ErbB RTKs as an
example. It is worthwhile mentioning here that ErbB2 is
the preferred heterodimeration partner for the other ErbB
family members. ErbB2-containing heterodimers have
more potent and prolonged signalling ability [18], provid-
ing an explanation for the propensity of this receptor to be
overexpressed in human cancer. ErbB2 overexpression
triggers ligand-independent activation of the kinase
domain, apparently as a result of spontaneous dimer for-
mation. Although ErbB2 homodimers alone very likely con-
tribute to malignancy, a number of observations, many
arising from the transgenic models of mammary cancer
that are discussed in the article by Andrechek and Muller
[3], suggest that ErbB2 cooperates with other ErbB
receptors, including EGF receptor and ErbB3, during the
malignant process. Many breast tumours that contain
ErbB2 also exhibit autocrine stimulation of EGF receptor
via expression of one of its numerous ligands (for review
[19]). The ability of ErbB2 to potentiate EGF receptor sig-
nalling, due to the formation of EGF receptor–ErbB2 het-
erodimers, would provide tumour cells with a more potent
growth stimulus and might lead to the activation of addi-
tional intracellular pathways. Furthermore, mammary
tumours derived from Neu transgenic mice also exhibit co-
overexpression of endogenous EGF receptor [20]. The
ErbB2–ErbB3 heterodimer appears to be the most potent
ErbB dimer with respect to proliferation and transforma-
tion [21]. Moreover, mammary tumours from Neu trans-
genic mice exhibit selective upregulation of ErbB3
expression and activity, suggesting that there might be
selective pressure for the ErbB2–ErbB3 heterodimer in
mammary cancer development [22]. Very recent results
from our laboratory indicate that overexpressed ErbB2
and ErbB3 cooperate during transformation [23] and as
therapeutic targets [24].
As these articles should make apparent, our increasing
knowledge on the specific molecular alterations in breast
tumours has paved the way for the development of thera-
peutic agents that are customized to the tumour, recogniz-
ing and inhibiting the proteins responsible for the
malignant phenotype. One exciting example of a rational,
targeted approach to breast cancer treatment is Her-
ceptin™ (Genentech, San Francisco, California, USA), a
recombinant humanized antibody targeted to ErbB2. Its
development as a therapeutic agent followed from experi-
mental observations that certain antibodies that bind the
extracellular domain of ErbB2 inhibit the growth of tumour
cells that overexpress that receptor [25]. Herceptin has
shown clinical efficacy in ErbB2-overexpressing breast
cancer patients, and is now being used for the treatment
of advanced breast cancer [26]. Finally, considering the
concept of cooperativity between proteins that induce
breast cancer, it is likely that therapeutic combinations
directed at multiple molecular targets may prove to be
more efficacious than monospecific therapy in the treat-
ment of breast cancer.
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